Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets generic and specialty medicines, as well as biopharmaceutical products. Its customer base includes healthcare providers, hospitals, and pharmacies across North America, Europe, and other international markets. Revenue primarily comes from the sale of generic medicines (approximately 60%), specialty medicines (around 30%), and active pharmaceutical ingredients (about 10%). Factors supporting Teva's endurance include its extensive product portfolio and established market presence, while challenges include pricing pressures in the generic market and regulatory hurdles.
—
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets generic and specialty medicines, as well as biopharmaceutical products. Its customer base includes healthcare providers, hospitals, and pharmacies across North America, Europe, and other international markets. Revenue primarily comes from the sale of generic medicines (approximately 60%), specialty medicines (around 30%), and active pharmaceutical ingredients (about 10%). Factors supporting Teva's endurance include its extensive product portfolio and established market presence, while challenges include pricing pressures in the generic market and regulatory hurdles.
—
Daily adjusted close
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets generic and specialty medicines, as well as biopharmaceutical products. Its customer base includes healthcare providers, hospitals, and pharmacies across North America, Europe, and other international markets. Revenue primarily comes from the sale of generic medicines (approximately 60%), specialty medicines (around 30%), and active pharmaceutical ingredients (about 10%). Factors supporting Teva's endurance include its extensive product portfolio and established market presence, while challenges include pricing pressures in the generic market and regulatory hurdles.